Meng Jiawei, Zhu Yingying, Wang Hao, Cao Hongzhi, Mu Wanmeng
State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, People's Republic of China.
Bloomage Biotechnology Corporation, Limited, Jinan, Shandong 250010, People's Republic of China.
J Agric Food Chem. 2023 Feb 8;71(5):2234-2243. doi: 10.1021/acs.jafc.2c08436. Epub 2023 Jan 26.
Human milk oligosaccharides (HMOs) have unique beneficial effects for infants and are considered as the new gold standard for premium infant formula. They are a collection of unconjugated glycans, and more than 200 distinct structures have been identified. Generally, HMOs are enzymatically produced by elongation and/or modification from lactose via stepwise glycosylation. Each glycosylation requires a specific glycosyltransferase (GT) and the corresponding nucleotide sugar donor. In this review, the typical HMO-producing GTs and the one-pot multienzyme modules for generating various nucleotide sugar donors are introduced, the principles for designing the enzyme cascade routes for HMO synthesis are described, and the important metabolic engineering strategies for mass production of HMOs are also reviewed. In addition, the future research directions in biotechnological production of HMOs were prospected.
人乳寡糖(HMOs)对婴儿具有独特的有益作用,被视为优质婴儿配方奶粉的新黄金标准。它们是一组未结合的聚糖,已鉴定出200多种不同的结构。一般来说,HMOs是通过乳糖经逐步糖基化进行延伸和/或修饰而酶促产生的。每次糖基化都需要特定的糖基转移酶(GT)和相应的核苷酸糖供体。在本综述中,介绍了典型的产生HMO的GTs和用于生成各种核苷酸糖供体的一锅多酶模块,描述了设计HMO合成酶级联途径的原理,还综述了HMO大规模生产的重要代谢工程策略。此外,还展望了HMO生物技术生产的未来研究方向。